---

Steps in discovery of alogliptin

Full Text PDF

---

Review Article

Author Details : Abhijit Tailokya, Sunil Chaudhry*, Gopal Wawde, Yogesh Bhide, Kavita Inamdar

Volume : 11, Issue : 2, Year : 2024

Article Page : 136-140

https://doi.org/10.18231/j.ijpca.2024.018

Suggest article by email

Get Permission

Abstract

Alogliptin was initially approved to treat T2DM in Japan in 2010 and then approved by FDA and by EMA in 2013. Alogliptin, a highly potent and selective, noncovalent inhibitor of DPP-4. Inhibition of DPP-4 activity, alogliptin slows the inactivation of incretin hormones, glucagon-like peptide-1 (GLP-1). In terms of drug safety alogliptin is generally well-tolerated, with a low risk of hypoglycemia, weight gain, acute pancreatitis, and hepatotoxicity. Alogliptin has been effectively combined with Metformin or Pioglitazone to provide better glycaemic control. The drug can be used in mild hepatic or renal impairment with appropriate dosage adjustment. Treatment with alogliptin has shown less weight gain compared with sulfonylureas. Alogliptin and FDC of Alogliptin + Metformin approved and available in India with brand name Aloja & Aloja M/Forte, with well documented safety and efficacy through phase IV study conducted in India.

Keywords: DPP4i, T2DM, GLP1, GIP, atherogenic, lipids/adipose, tissue insulin resistance

How to cite : Tailokya A, Chaudhry S, Wawde G, Bhide Y, Inamdar K, Steps in discovery of alogliptin. Int J Pharm Chem Anal 2024;11(2):136-140

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.